Recombinant varicella-zoster antigen as well as preparation method and application thereof

Through codon optimization and adjuvant binding, the varicella zoster virus gE protein is highly expressed in Pichia yeast, solving the problems of low expression efficiency and high cost in the prior art, and achieving low-cost vaccine research and development and effective Immune response.

CN119061037AActive Publication Date: 2024-12-03INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411157866.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-12-03
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

The existing recombinant protein expression system is inefficient and costly when expressing the glycoprotein E (gE) of the varicella zoster virus, and it is difficult to meet the needs of low-cost vaccine development.

Method used

Through codon optimization design of the varicella zoster virus gE gene, the expression vector is constructed to achieve efficient expression in Pichia cerevisiae, and combined with appropriate adjuvants (such as AS01, aluminum salt + CpG ODN) to improve the immunogenicity of the antigen.

Benefits of technology

It has achieved efficient expression of varicella zoster virus gE protein in the Pichia system, which has strong immunogenicity, is suitable for industrial scale production, and induces effective immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061037A_ABST
    Figure CN119061037A_ABST
Patent Text Reader

Abstract

The invention discloses a recombinant varicella-zoster antigen as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The recombinant varicella-zoster antigen disclosed by the invention comprises a VZV-gE protein with an amino acid sequence as shown in SEQ ID NO. 1. The gE protein gene sequence of the varicella-zoster virus is optimally designed, a recombinant expression vector is constructed, high-efficiency expression of the recombinant gE protein can be realized on pichia pastoris, and a high-efficiency expression strain is easy to obtain. The recombinant varicella-zoster virus gE protein (VZV-gE) prepared by the invention is suitable for preparing vaccines after being matched with adjuvants, has good immunogenicity and can induce good immune response.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and more specifically to a recombinant varicella zoster antigen and a preparation method and application thereof. Background Art

[0002] Recombinant protein expression technology refers to a technical means of expressing the foreign protein in the expression system cells in the form of a free plasmid or integrated into the vector genome under certain conditions. At present, the mainstream recombinant protein expression systems include yeast expression systems, prokaryotic expression systems such as Escherichia coli, mammalian cell expression systems, and plant cell expression systems. Among them, the Pichia pastoris expression system is an important expression system for recombinant protein preparation and vaccine development in developing countries due to its high yield, low cost, high-density fermentation, and a certain degree of post-translational modification. Recombinant protein expression technology is an important foundation for many research fields such as biology and biopharmaceuticals today, and has a wide range of applications in protein function research and vaccine development. Among them, recombinant protein expression is a key technology in the development of recombinant protein vaccines. The development of coding sequences that can efficiently express foreign proteins is of great significance for the development of recombinant protein vaccines.

[0003] A codon refers to three consecutive different nucleotides arranged according to certain rules in a nucleic acid sequence that encodes a protein. Different nucleotide combinations correspond to different amino acids. Different expression systems have different codon preferences. Even in the same expression system, different codon usage will greatly affect the expression efficiency of the recombinant protein. Codon optimization is generally based on the codon usage frequency for different amino acids in the corresponding species, taking into account factors such as the GC content in the coding sequence. Therefore, the coding sequences corresponding to the same protein may vary greatly, and the efficiency of expressing exogenous proteins may also vary greatly.

[0004] Varicella Zoster Virus (VZV) is a highly contagious virus that can cause chickenpox in children, remain dormant in the body after recovery, and cause shingles in adults with low immunity, such as the elderly. The main immunogenicity of VZV is concentrated on its glycoprotein E (gE), and the VZV recombinant protein vaccines currently on the market all use gE as an antigen. Therefore, the preparation of gE based on the Pichia pastoris expression system is of great significance for the development of low-cost varicella zoster vaccines to improve the level of public health prevention and control of varicella zoster in my country. Summary of the invention

[0005] In view of this, the present invention provides a recombinant varicella zoster antigen and a preparation method and application thereof.

[0006] In order to achieve the above object, the present invention adopts the following technical solution:

[0007] A polynucleotide comprising a signal peptide nucleotide sequence as shown in SEQ ID NO.3 and a VZV-gE nucleotide sequence as shown in SEQ ID NO.2.

[0008] Another object of the present invention is to provide a recombinant protein, wherein the recombinant protein is encoded by the above polynucleotide.

[0009] Another object of the present invention is to provide a biological material, which comprises the above-mentioned polynucleotide.

[0010] Preferably, the expression vector of the biological material is a Pichia pastoris expression vector.

[0011] Another object of the present invention is to provide a cell line, the genome of which is integrated with the polynucleotide described above, or the cell line comprises the biological material described above.

[0012] Another object of the present invention is to provide a recombinant varicella zoster antigen, wherein the antigen comprises the VZV-gE protein having an amino acid sequence as shown in SEQ ID NO.1.

[0013] Another object of the present invention is to provide a method for preparing the above-mentioned recombinant varicella zoster antigen, comprising the following steps:

[0014] S1: artificially synthesized varicella zoster virus codon-optimized gE gene, the nucleotide sequence of which is shown in SEQ ID NO.2;

[0015] S2: Add the signal peptide sequence shown in SEQ ID NO.3 before the codon-optimized gE gene obtained in step S1, and construct an expression vector in the order of pMT-V5 vector-signal peptide-gE protein-6xHis tag-pMT-V5 vector to obtain a VZV-gE expression vector;

[0016] S3: transforming the VZV-gE expression vector obtained in step S2 into Pichia pastoris competent cells; inducing with methanol; and collecting the induced supernatant;

[0017] S4: Filter, concentrate and purify the induced supernatant obtained in step S3 to obtain recombinant varicella zoster antigen.

[0018] Another object of the present invention is to provide an immunogen, which is the above-mentioned recombinant protein or the above-mentioned recombinant varicella zoster antigen.

[0019] Another object of the present invention is to provide the use of the above-mentioned recombinant protein or the above-mentioned recombinant varicella zoster antigen in the preparation of a product for preventing varicella zoster virus infection.

[0020] Another object of the present invention is to provide a pharmaceutical composition for preventing varicella-zoster virus infection, the pharmaceutical composition comprising the above-mentioned recombinant protein or the above-mentioned varicella-zoster virus antigen, and a pharmaceutically acceptable carrier.

[0021] Preferably, the pharmaceutically acceptable carrier is an adjuvant, and the adjuvant is AS01, aluminum salt+CpG ODN.

[0022] Beneficial effects:

[0023] (1) Ease of obtaining efficient expression strains: The present invention optimizes the design of the gE protein gene sequence of varicella-zoster virus and constructs a recombinant expression vector, which can achieve efficient expression of the recombinant gE protein in Pichia pastoris.

[0024] (2) Easy to scale up for industrial production: The yeast expression system is simple to culture, grows rapidly, is suitable for high-density fermentation, and is low-cost, with a high level of exogenous protein expression.

[0025] (3) Good stability: The recombinant protein expression vector can be integrated into the genome of the host yeast by homologous recombination, is not easily lost, and the product is not easily degraded.

[0026] (4) The recombinant varicella zoster virus gE protein (VZV-gE) produced by the present invention is suitable for preparing vaccines after being combined with an adjuvant, has strong immunogenicity and can induce a good immune response. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0028] Figure 1 This is the map of the Pink-HC-VZV-gE expression vector.

[0029] Figure 2 is the expression effect of recombinant gE protein, where M is Protein Marker; empty is the supernatant of pPink-HC empty vector; 0 is the uninduced supernatant; 1.1-1.3 are the supernatants of 24h, 48h, and 72h induced by sig1gE, respectively.

[0030] Figure 3 The results of nickel ion column purification of recombinant gE protein; A is: Western Blot, SDS-PAGE and Coomassie Brilliant Blue staining; B is Western Blot of VZV-gE recombinant protein after nickel ion column purification; (M is ProteinMarker; Blank is empty load after pPink-HC transfection; Original is concentrated stock solution of yeast cell induction supernatant; Flow is the flow-through collected during loading; Wash is the eluate in the equilibrium stage; 1-13 are the gradient eluates collected in each time period; the red arrow marks the main peak containing VZV-gE recombinant protein; the red box marks VZV-gE recombinant protein; the antibody is mouse monoclonal antibody against VZV-gE protein); C is the peak graph of nickel ion column purification.

[0031] Figure 4 Analysis results of low N-glycosylation modified VZV-gE recombinant protein; wherein, (A) is SDS-PAGE and Coomassie Brilliant Blue staining, M is Protein Marker; + is glycoprotein staining positive control (horseradish peroxidase); - is negative control (soybean trypsin inhibitor); empty is pPink-HC empty vector; original is yeast cell induction supernatant stock solution; gE is VZV-gE recombinant protein; H is Endo H endoglycosidase; original (H) is Endo H endoglycosidase cleaved yeast cell induction supernatant stock solution; gE (H) is VZV-gE recombinant protein purified by nickel ion column treated with Endo H endoglycosidase; (B) is the glycoprotein staining corresponding to (A); (C) is SDS-PAGE and Coomassie Brilliant Blue staining of VZV-gE recombinant protein purified by nickel ion column treated with Endo H endoglycosidase; M is Protein Marker; empty is pPink-HC empty vector; H is Endo H endoglycosidase; original is yeast cell induction supernatant stock solution; 1-3 are VZV-gE recombinant proteins collected at different stages after nickel ion column purification treated with Endo H endoglycosidase; (D) is the grayscale analysis of "3" in (C); 1 is SDS-PAGE band 1 of "3" in (C) from top to bottom; 2 is SDS-PAGE band 2 of "3" in (C) from top to bottom; 3 is SDS-PAGE band 3 of "3" in (C) from top to bottom; the antibody used is mouse monoclonal antibody against VZV-gE protein.

[0032] Figure 5 The serum antibody levels of mice in different immunization groups at week 4; the IgG antibody value is the sample well OD 450 The nm value is the maximum dilution when the positive value is reached; positive value determination: positive value = 2.1*negative control well OD 450 nm value; when the sample is diluted 100 times, its OD 450If the nm value is still lower than the positive value, it is recorded as 50; one point in the figure represents one serum sample, and the short black solid line is the geometric mean ± standard deviation; ns means no significant difference, P>0.05; *: P<0.05; **: P<0.01; ***: P<0.001.

[0033] Figure 6 The percentages of CD4+T lymphocytes secreting IL-2, IL-10, and IFN-γ cytokines in the lymph nodes of mice under different immunization schemes; ns means no significant difference, P>0.05; *: P<0.05; **: P<0.01; ***: P<0.001.

[0034] Figure 7 The percentages of CD8+T lymphocytes secreting IL-2, IL-10, and IFN-γ cytokines in the lymph nodes of mice under different immunization schemes; ns means no significant difference, P>0.05; *: P<0.05; **: P<0.01; ***: P<0.001. DETAILED DESCRIPTION

[0035] The following specific examples are used to illustrate that the DNA sequence involved in the invention can prepare VZV-gE protein in the Pichia system and achieve the effect as a vaccine, but it should not be understood as a limitation of the present invention. Without departing from the spirit and essence of the present invention, the modification or replacement of the method, steps or conditions of the present invention all belongs to the scope of the present invention. The experimental methods in the following examples where specific conditions are not indicated are usually carried out under conventional conditions, such as the conditions described in "Molecular Cloning: Laboratory Manual".

[0036] Example 1 Construction of expression vector

[0037] The varicella zoster virus gE sequence involved in the present invention is obtained from the National Center for Biotechnology Information (NCBI) of the United States. The gene sequence and amino acid sequence (NC_001348.1) of ORF68 in the VZV Dumas strain are obtained, the original secretion signal peptide is removed, and its N-terminal aa25-539 (SEQ ID NO.1) is intercepted, and the codon optimization platform of Jinweizhi Company is used to optimize the codons according to the preference of Pichia pastoris, so that the gene is more suitable for expression in Pichia pastoris (SEQ ID NO.2). The gene fragment after codon optimization is handed over to Sangon Biotech (Shanghai) Co., Ltd. for gene synthesis. The signal peptide sequence uses α-mating factor pre-sequence (SEQ ID NO.3), and the expression vector is constructed in the order of pMT-V5 vector-signal peptide-gE protein-6xHis tag-pMT-V5 vector to obtain Pink-HC-VZV-gE expression vector, as shown in the attached Figure 1 The core elements of the vector include: a promoter, a terminator, a replicon, a Kozak sequence, a resistance gene and a VZV-gE insertion segment.

[0038] SEQ ID NO.1:

[0039] MTNPVRASVLRYDDFHTDEDKLDTNSVYEPYYHSDHAESSWVNRGESSRKAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDRHKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAIQHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPGVLKVLRTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLAMHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHLAQRVASTVYQNCEHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYA;

[0040] SEQ ID NO.2:

[0041]

[0042] SEQ ID NO.3:

[0043] ATGAGATTTCCTTCAATTTTTACTGCTGTTTTATTCGCAGCATCCTCCGCATTAGC T.

[0044] Example 2 Induced expression of Pichia pastoris strains and purification of VZV-gE protein

[0045] The expression vector successfully connected with VZV-gE was transformed into Pichia pastoris competent cells by electroporation, and inoculated on PAD selection plates, placed in a 28.8°C incubator for 5-10 days, and white monoclones with good growth were picked and inoculated into BMGY liquid medium, and cultured at 280rpm and 28.8°C for 48h. The bacterial liquid was collected in a 50mL centrifuge tube, centrifuged at 1500xg for 5min, the supernatant was discarded, and the culture was resuspended in an equal volume of BMMY medium for induction. 4% methanol was added for 24h to continue induction, and the induced supernatant was collected at 24h, 48h and 72h.

[0046] The yeast cell induction supernatant was filtered with a 0.22 μm filter membrane, and the filtered induction supernatant was concentrated with a 10KD ultrafiltration membrane package VIVAFLOW 200. Then, the concentrated supernatant was replaced three times by centrifugation with ten times the volume of nickel ion column A solution (20 mM PBS, 0.5 M NaCl) in the 10KD ultrafiltration membrane package device. The sample was then concentrated through the Loop ring and loaded onto the nickel ion column. Five column volumes were balanced with nickel ion column A solution, and gradient elution was performed with nickel ion column B solution (20 mM PBS, 0.5 M NaCl, 0.5 M imidazole). From the beginning of elution, a tube of eluate was received for every 5 mL, and corresponding marks were made, and the eluate was collected.

[0047] Western Blot experiments showed that the recombinant gE protein was expressed to different extents after different induction times (see Appendix Figure 2 ), and the nickel ion column can effectively purify the recombinant gE protein (see Appendix Figure 3 ).

[0048] Example 3 De-N-glycosylation of gE recombinant protein

[0049] The VZV-gE recombinant protein purified by nickel ion column was de-N-glycosylated according to the instruction manual of Endo H endoglycosidase, and the treated samples were subjected to SDS-PAGE, Coomassie brilliant blue staining and glycogen staining (see Appendix Figure 4 ).

[0050] Example 4 Animal Immunization Experiment of Recombinant gE Protein

[0051] BALB / c female mice aged 6-8 weeks were randomly divided into 7 groups, 5 mice in each group; the first immunization was performed at week 0 by intramuscular injection, and the booster immunization was performed at the same dose at week 2. The control samples were PBS, Pink-HC-VZV-gE (Endo H) (obtained in Example 3) and 293-VZV-gE (gE protein obtained by the eukaryotic expression system 293T cell expression system), and the adjuvants were Al(OH)3 (aluminum salt), AS01 and CpG ODN. The specific groups are shown in Table 1. The tail vein blood of mice at week 0, week 2 and week 4 was collected using a coagulation tube, and the serum was separated (3000rpm, 4°C, centrifuged for 5min) and stored in a -20°C refrigerator for use. The immunoglobulin G (IgG) antibody level in the serum of mice immunized with VZV-gE recombinant protein was evaluated, and the secretion levels of lymphocytes and cytokines IL-2, IL-10, and IFN-γ were analyzed using flow cytometry.

[0052] Table 1

[0053]

[0054] Humoral (serum) immunity results can be seen (see Appendix Figure 5), at the second week, the antibody levels in the pPinkgE-Al(OH)3+CpG ODN group, the pPinkgE-AS01 group, the 293gE-Al(OH)3+CpG ODN group, and the 293gE-AS01 group were significantly increased. The antibody titers of mice were detected at the 4th week (2 weeks after 2 doses of immunization) after immunization with different immunization schemes (pPinkgE, pPinkgE(H), 293gE combined with aluminum salt + CpG ODN and AS01 adjuvant, respectively). The geometric mean titers (GMT values) of antibodies produced by mice with 6 different immunization schemes were as follows: pPinkgE-ASO1 (85196), pPinkgE-aluminum salt + CpG ODN2395 (45875), 293gE-aluminum salt + CpG ODN 2395 (26214), 293gE-AS01 (26214), pPinkgE(H)-aluminum salt + CpG ODN (24576) and pPinkgE (H) + AS01 (18022) indicated that the highly N-glycosylated VZV-gE expressed by Pichia pastoris could induce mice to produce higher antibody levels than VZV-gE expressed by 293T cells. The serum GMT value of mice in the pPinkgE-ASO1 group was greater than that in the pPinkgE-aluminum salt + CpG ODN group, and the difference was statistically significant (P<0.05), indicating that the ability of aluminum salt combined with CpG ODN adjuvant to induce the antibody level produced by mice was slightly inferior to that of AS01 adjuvant; secondly, the GMT value of mice in the pPinkgE-ASO1 group was greater than that in the pPinkgE(H) + AS01 group, and the difference was statistically significant (P<0.001), and the serum GMT value of mice in the pPinkgE-aluminum salt + CpG ODN group was also higher than that in the pPinkgE(H)-aluminum salt + CpG ODN group, indicating that the high N-glycosylated VZV-gE produced by the Pichia pastoris expression system combined with AS01 adjuvant or aluminum salt combined with CpG ODN can induce mice to produce stronger antibody levels than the low-glycosylated VZV-gE produced by the Pichia pastoris expression system; furthermore, the serum GMT value of mice in the pPinkgE-ASO1 group was higher than that in the pPinkgE-ASO1 group, and the difference was statistically significant (P<0.001), and the serum GMT value of mice in the pPinkgE-aluminum salt + CpG ODN group was higher than that in the 293gE-aluminum salt + CpG ODN group, indicating that compared with VZV-gE produced by the eukaryotic expression system 293T, VZV-gE expressed by Pichia pastoris can induce mice to produce higher antibody levels.

[0055] By measuring the antibody level and antibody titer after immunizing mice with different immunization schemes (pPinkgE, pPinkgE (H), 293gE combined with aluminum salt + CpG ODN and AS01 adjuvant, respectively), it was found that, except for the PBS group, the serum antibody level and antibody titer of other immunization groups at 0, 2, and 4 weeks increased gradually. At 4 weeks (2 weeks after 2 doses of immunization), the serum antibody titers of all experimental groups were greater than 18022, and the highest antibody geometric mean titer could reach 85196. The highly glycosylated VZV-gE produced by the Pichia pastoris expression system combined with AS01 adjuvant can induce mice to produce a stronger humoral immune response than the lowly glycosylated VZV-gE produced by the Pichia pastoris expression system; the highly glycosylated VZV-gE produced by the Pichia pastoris expression system combined with AS01 adjuvant or aluminum salt combined with CpG ODN can induce mice to produce a stronger humoral immune response than the VZV-gE produced by the eukaryotic expression system 293 cells.

[0056] Immunization results can be seen (see Appendix Figure 6 , 7 ), CD4+T cells and CD8+T cells secreting IL-2, IL-10 and IFN-γ were present in the lymph nodes of mice in each group, among which the group with the highest proportion of CD4+T cells secreting IL-2 was the pPinkgE-aluminum salt + CpGODN group, followed by the pPinkgE(H)-aluminum salt + CpG ODN group. The group with the highest proportion of CD4+T cells secreting IL-10 was the pPinkgE(H)-aluminum salt + CpG ODN group, suggesting that the de-N-glycosylated recombinant varicella-zoster virus glycoprotein E vaccine produced by the Pichia pastoris expression system may induce stronger Th2-type cellular immunity while maintaining the Th1-type cellular immune response ability. The group with the highest proportion of CD4+T cells secreting IFN-γ was the 293gE-aluminum salt + CpG ODN group, followed by the 293gE-AS01 group. There was a significant difference between the 293gE-aluminum salt + CpG ODN group and the pPinkgE-aluminum salt + CpG ODN group (P<0.05), and there was a significant difference between the 293gE-aluminum salt + CpG ODN group and the pPinkgE-AS01 group and the pPinkgE(H)-aluminum salt + CpG ODN group (P<0.01), suggesting that aluminum salt combined with CpG ODN adjuvant may induce a stronger Th1 cellular immune response.

[0057] The results showed that highly N-glycosylated VZV-gE expressed by Pichia pastoris could induce more effective humoral and cellular immune responses in mice than low N-glycosylated VZV-gE; compared with AS01, aluminum salt combined with CpG ODN adjuvant could induce stronger Th1 type cellular immune response in VZV-gE recombinant protein vaccine; highly N-glycosylated VZV-gE expressed by Pichia pastoris combined with aluminum salt combined with CpG ODN adjuvant could more effectively induce IL-2 secretion in CD4+T cells, while VZV-gE combined with aluminum salt combined with CpG ODN adjuvant could more effectively induce IFN-γ secretion in CD4+T cells.

[0058] In summary, the recombinant gE protein can successfully induce good humoral and cellular immune responses and has important potential value for use as a vaccine.

[0059] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.

[0060] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A polynucleotide, characterized in that The polynucleotide comprises a signal peptide nucleotide sequence as shown in SEQ ID NO.3, and a VZV-gE nucleotide sequence as shown in SEQ ID NO.

2.

2. A recombinant protein, characterized in that The recombinant protein is encoded by the polynucleotide according to claim 1.

3. A biomaterial, characterized in that: The biological material comprises the polynucleotide of claim 1.

4. The biomaterial according to claim 3, characterized in that The expression vector of the biological material is a Pichia pastoris expression vector.

5. A cell line, characterized in that The polynucleotide of claim 1 is integrated into the genome of the cell line, or the cell line comprises the biological material of claim 3 or 4.

6. A recombinant varicella zoster antigen, characterized in that: The antigen includes the VZV-gE protein with an amino acid sequence as shown in SEQ ID NO.

1.

7. The method for preparing the recombinant varicella zoster antigen according to claim 6, characterized in that: The following steps are involved: S1: artificially synthesized varicella zoster virus codon-optimized gE gene, the nucleotide sequence of which is shown in SEQ ID NO.2; S2: Add the signal peptide sequence shown in SEQ ID NO.3 before the codon-optimized gE gene obtained in step S1, and construct an expression vector in the order of pMT-V5 vector-signal peptide-gE protein-6xHis tag-pMT-V5 vector to obtain a VZV-gE expression vector; S3: transforming the VZV-gE expression vector obtained in step S2 into Pichia pastoris competent cells; inducing with methanol; and collecting the induced supernatant; S4: Filter, concentrate and purify the induced supernatant obtained in step S3 to obtain recombinant varicella zoster antigen.

8. An immunogen, characterized in that The immunogen is the recombinant protein according to claim 2 or the recombinant varicella zoster antigen according to claim 6.

9. Use of the recombinant protein according to claim 2 or the recombinant varicella zoster antigen according to claim 6 in the preparation of a product for preventing varicella zoster virus infection.

10. A pharmaceutical composition for preventing varicella zoster virus infection, characterized in that: The pharmaceutical composition comprises the recombinant protein according to claim 2 or the varicella-zoster virus antigen according to claim 6, and a pharmaceutically acceptable carrier.

Citation Information

Patent Citations

  • Expression method of VZV glycoprotein to pichia pastoris and application of expression method

    CN108383897A

  • Chickenpox-zoster virus glycoprotein E gene expression vector, recombinant yeast strain thereof and application thereof

    CN109234302A

  • gE gene and carrier capable of expressing gE gene

    CN112142828A

  • Varicella-zoster virus recombinant fusion protein and application thereof

    CN116731210A

  • Antigen peptide and vaccine composition and application thereof

    CN117886899A